专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005102287A3 PHARMACEUTICAL COMPOSITIONS FOR ACUTE GLUCOCORTICOID THERAPY 审中-公开
标题翻译：用于急性葡萄糖激素治疗的药物组合物
公开(公告)号：WO2005102287A3
公开(公告)日：2006-06-22
申请号：PCT/EP2005004399
申请日：2005-04-21
申请人： DUOCORT AB , SKRTIC STANKO , JOHNSSON JOERGEN , LENNERNAES HANS , HEDNER THOMAS , JOHANNSSON GUDMUNDUR
发明人： SKRTIC STANKO , JOHNSSON JOERGEN , LENNERNAES HANS , HEDNER THOMAS , JOHANNSSON GUDMUNDUR
IPC分类号： A61K31/573 , A61K20060101 , A61K9/00 , A61K9/08 , A61K9/12 , A61K9/16 , A61K9/20 , A61K9/50 , A61K9/70
CPC分类号： A61K9/0095 , A61K9/006 , A61K9/2018 , A61K9/5078 , A61K9/7007 , A61K31/00 , A61K31/573
摘要： The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid
摘要翻译：本发明涉及用于需要急性糖皮质激素治疗的急性紧急情况下的含糖皮质激素的药物组合物或试剂盒。值得注意的是，本发明涉及被设计为由医院外的非医学训练者或其他医学或临床环境施用的药物组合物和试剂盒。本发明还涉及通过提供糖皮质激素的快速起效来治疗需要急性糖皮质激素治疗的疾病的方法

2. 发明申请

WO2005088315A1 RECOMBINANT HUMAN TSH IN THE DIAGNOSIS OF CENTRAL HYPOTHYROIDISM 审中-公开
标题翻译：重组人TSH在诊断中枢红细胞生成
公开(公告)号：WO2005088315A1
公开(公告)日：2005-09-22
申请号：PCT/SE2005/000364
申请日：2005-03-14
申请人： SAHLTECH I GÖTEBORG AB , NYSTRÖM, Ernst , JOHANNSSON, Gudmundur , FILIPSSON, Helena
发明人： NYSTRÖM, Ernst , JOHANNSSON, Gudmundur , FILIPSSON, Helena
IPC分类号： G01N33/74
CPC分类号： G01N33/76 , G01N33/78
摘要： The present invention relates to the use of recombinant human TSH for diagnosing hypothyroidism. Specifically, the present invention pertains to the use of recombinant human TSH for diagnosing central hypothyroidism.
摘要翻译：本发明涉及重组人TSH用于诊断甲状腺功能减退症的用途。具体地，本发明涉及重组人TSH用于诊断中枢性甲状腺功能减退症的用途。

3. 发明申请

WO2003090754A1 USE OF DHEA FOR TREATMENT OF FEMALE HYPOPITUITARISM 审中-公开
标题翻译：使用DHEA治疗女性超声心动图
公开(公告)号：WO2003090754A1
公开(公告)日：2003-11-06
申请号：PCT/SE2003/000644
申请日：2003-04-22
申请人： SAHLTECH I GÖTEBORG AB , BENGTSSON, Bengt-Åke , JOHANNSSON, Gudmundur
发明人： BENGTSSON, Bengt-Åke , JOHANNSSON, Gudmundur
IPC分类号： A61K31/56
CPC分类号： A61K31/56
摘要： Low-dose of dehydroepiandrosterone affects behaviour in hypopituitary and non-deficient women.
摘要翻译：低剂量的脱氢表雄甾酮影响了垂体和非缺乏妇女的行为。

4. 发明申请

WO1997038709A1 USE OF GROWTH HORMONE 审中-公开
标题翻译：使用生长激素
公开(公告)号：WO1997038709A1
公开(公告)日：1997-10-23
申请号：PCT/SE1997000601
申请日：1997-04-10
申请人： PHARMACIA & UPJOHN AB , JOHANNSSON, Gudmundur , MÅRIN, Per , LÖNN, Lars , OTTOSSON, Malin , STENLÖF, Kaj , BJÖRNTORP, Per , SJÖSTRÖM, Lars , BENGTSSON, Bengt-Åke
发明人： PHARMACIA & UPJOHN AB
IPC分类号： A61K38/27
CPC分类号： A61K38/27
摘要： The invention relates to the use of growth hormone, preferably human growth hormone or analogues thereof for the manufacturing of a medicament for treatment of individuals with the Metabolic syndrome. They include individuals with abdominal/visceral obesity and its metabolic and circulatory consequences including insulin resistance, lipoprotein aberrations and hypertension. The medicament is also used to increase insulin sensitivity and for treatment and prevention of non-insulin dependent diabetes mellitus.
摘要翻译：本发明涉及生长激素，优选人生长激素或其类似物在制备用于治疗具有代谢综合征的个体的药物中的用途。它们包括具有腹部/内脏肥胖症的个体及其代谢和循环后果，包括胰岛素抵抗，脂蛋白异常和高血压。该药物还用于增加胰岛素敏感性和用于治疗和预防非胰岛素依赖性糖尿病。

5. 发明申请

WO2005102271A3 PHARMACEUTICAL COMPOSITIONS FOR GLUCOCORTICOID REPLACEMENT THERAPY 审中-公开
标题翻译：用于葡萄糖替代治疗的药物组合物
公开(公告)号：WO2005102271A3
公开(公告)日：2006-08-03
申请号：PCT/EP2005004400
申请日：2005-04-21
申请人： DUOCORT AB , SKRTIC STANKO , JOHNSSON JOERGEN , LENNERNAES HANS , HEDNER THOMAS , JOHANNSSON GUDMUNDUR
发明人： SKRTIC STANKO , JOHNSSON JOERGEN , LENNERNAES HANS , HEDNER THOMAS , JOHANNSSON GUDMUNDUR
IPC分类号： A61K9/20 , A61K20060101 , A61K9/00 , A61K9/24
CPC分类号： A61K31/573 , A61K9/2031 , A61K9/209 , A61K9/28
摘要： The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents. The invention also relates to a kit comprising a first and a second component, the first component designed to release one or more glucocorticoids substantially immediately and the second component is designed to release one or more glucocorticoids over an extended period of time of at least 8 hours. The invention also relates to a method for treating diseases requiring glucocorticoid treatment such as in subjects having a glucocorticoid deficiency disorder. In another aspect the invention relates to the use of a first and a second amount of one or more glucocorticoids for the preparation of a pharmaceutical composition or kit for the treatment of a glucocorticoid deficiency disorder.
摘要翻译：本发明涉及糖皮质激素替代疗法，并且提供药物组合物和试剂盒，其设计用于将一种或多种糖皮质激素递送至有需要的受试者，其方式使得糖皮质激素的血清水平基本上模拟健康受试者在临床相关期间的时间。药物组合物包含一种或多种糖皮质激素，其中一种或多种糖皮质激素的第一部分基本上立即释放，并且一种或多种糖皮质激素的第二部分在至少约8小时的延长时间内释放，表示为氢化可的松当量的第一部分的一种或多种糖皮质激素在总氢化可的松当量的约15至约50％的范围内。本发明还涉及包含第一和第二组分的试剂盒，第一组分被设计成基本上立即释放一种或多种糖皮质激素，并且第二组分被设计成在至少8小时的延长的时间段内释放一种或多种糖皮质激素。本发明还涉及治疗需要糖皮质激素治疗的疾病的方法，例如具有糖皮质激素缺乏症的受试者。在另一方面，本发明涉及第一和第二量的一种或多种糖皮质激素在制备用于治疗糖皮质激素缺乏症的药物组合物或试剂盒中的用途。

6. 发明申请

WO2016083325A1 TREATMENT OF SKIN ATROPHY WITH A COMBINATION OF TRIIODOTHYROACETIC ACID (TRIAC) AND DEHYDROEPIANDROSTERONE (DHEA) 审中-公开
标题翻译：用TRIIOTOTHYROACTICACID（TRIAC）和脱氢叶酸酯（DHEA）的组合处理皮肤ATROPHY
公开(公告)号：WO2016083325A1
公开(公告)日：2016-06-02
申请号：PCT/EP2015/077401
申请日：2015-11-24
申请人： FAERGEMANN, Jan , JOHANNSSON, Gudmundur , OHLSSON, Claes , BATCHELLER, Derek Gregory , JOHNSSON, Jörgen , TÖRNELL, Jan
发明人： FAERGEMANN, Jan , JOHANNSSON, Gudmundur , OHLSSON, Claes , BATCHELLER, Derek Gregory , JOHNSSON, Jörgen , TÖRNELL, Jan
IPC分类号： A61K31/192 , A61K31/5685 , A61P17/18 , A61P17/16 , A61P17/10 , A61P17/08 , A61P17/06 , A61P17/02 , A61P17/00
CPC分类号： A61K31/5685 , A61K8/06 , A61K8/062 , A61K8/365 , A61K8/63 , A61K9/0014 , A61K9/06 , A61K9/107 , A61K31/192 , A61K45/06 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/08 , A61P17/10 , A61P17/16 , A61P17/18 , A61Q19/00 , A61Q19/08 , A61K2300/00
摘要： The aim of the present study was to investigate the effect of a combination of triiodothyroacetic acid (TRIAC) and dehydroepiandrosterone (DHEA) compared with TRIAC, DHEA or placebo alone on corticosteroid induced effect on collagen synthesis in humans. Six healthy male human volunteers aged 40-65 participated. Four areas of abdominal skin were pre-treated for 3 weeks with betamethasone valerate cream. The same areas were then treated with one of the following alternatives in the same cream vehicle: TRIAC, DHEA, TRIAC+DHEA and placebo for 2 weeks. Then suction blisters were raised in each of these areas with a vacuum pump. The blister fluid from each area was collected and frozen until analysis. Analysis of amino terminal propeptide of human type I procollagen (PINP) in suction blister fluid was performed using a commercially available immunoassay (Orion Diagnostics) kit. This study has for the first time shown that a combination of TRIAC and DHEA could effectively stimulate collagen synthesis in skin pretreated with betamethasone valerate demonstrated by an increase in PINP, and that the combination was more effective than TRIAC or DHEA alone. This combination could be used to effectively treat skin atrophy in corticosteroid induced skin atrophy. It could also be used to treat skin atrophy due to other circumstances such as e. g. sun damaged skin and skin atrophy due to high age. Another interesting application would be to combine TRIAC and DHEA with a potent corticosteroid in order to prevent corticosteroid induced skin atrophy. If this combination still is effective in the treatment of eczema and psoriasis and without the risk of skin atrophy this combination will be a major breakthrough for the use of potent topical corticosteroids.
摘要翻译：本研究的目的是调查三碘甲基乙酸（TRIAC）和脱氢表雄酮（DHEA）的组合与单独的TRIAC，DHEA或安慰剂组合对皮质类固醇诱导人类胶原合成的影响。参加了六十岁的40-65岁健康男性志愿者。用倍他米松戊酸酯霜预处理4个腹部皮肤区域3周。然后在相同的奶油载体中使用以下替代物之一处理相同的区域：TRIAC，DHEA，TRIAC + DHEA和安慰剂2周。然后用真空泵将这些区域中的每个区域吸起水泡。收集每个区域的水泡液，冷冻至分析。使用市售的免疫测定（Orion Diagnostics）试剂盒进行吸入泡状液中人I型前胶原（PINP）的氨基末端前肽的分析。这项研究首次表明，TRIAC和DHEA的组合可以有效地刺激皮下预处理的皮肤胶原蛋白合成，通过PINP增加证明戊酸倍他米松，并且该组合比单独的TRIAC或DHEA更有效。这种组合可用于有效治疗皮质类固醇诱导的皮肤萎缩中的皮肤萎缩。它也可以用于治疗由于其他情况如e的皮肤萎缩。 G。太阳损伤皮肤和皮肤萎缩由于年龄高。另一个有趣的应用是将TRIAC和DHEA与强效皮质类固醇结合，以防止皮质类固醇诱导的皮肤萎缩。如果这种组合在治疗湿疹和牛皮癣方面仍然有效，并且没有皮肤萎缩的风险，则这种组合将是使用强效局部皮质类固醇的重大突破。

7. 发明申请

WO2011144327A1 POSOLOGY AND ADMINISTRATION OF GLUCOCORTICOID BASED COMPOSITIONS 审中-公开
标题翻译：基于GLUCOCORTICOID的组合物的生物学和药理学
公开(公告)号：WO2011144327A1
公开(公告)日：2011-11-24
申请号：PCT/EP2011/002466
申请日：2011-05-18
申请人： DUOCORT PHARMA AB , HEDNER, Thomas , SIMONSSON, Ulrika, Sigrida, Helena , JOHANNSSON, Gudmundur , LENNERNÄS, Hans , SKRTIC, Stanko
发明人： HEDNER, Thomas , SIMONSSON, Ulrika, Sigrida, Helena , JOHANNSSON, Gudmundur , LENNERNÄS, Hans , SKRTIC, Stanko
IPC分类号： A61K31/573 , A61P5/44 , A61K9/00
CPC分类号： A61K31/573 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K9/209 , A61K9/28 , G01N33/743
摘要： The present invention relates to an improved method of administration of glucocorticoid based compositions in glucocorticoid replacement therapies enabling an objectively based regimen for administration enabling correct individual dosing of glucocorticoids resulting in an optimised individual replacement therapy and thus an improved long-term outcome for patients with temporary or chronic adrenal insufficiency.
摘要翻译：本发明涉及一种在糖皮质激素替代疗法中施用基于糖皮质激素的组合物的改进方法，其使得能够基于客观的方案进行给药，从而能够对糖皮质激素进行正确的个体给药，从而导致优化的个体替代疗法，从而改善临时患者的长期结果或慢性肾上腺功能不全。

8. 发明申请

WO2003039578A1 TREATMENT OF CONGESTIVE HEART FAILURE 审中-公开
标题翻译：治疗心绞痛失败
公开(公告)号：WO2003039578A1
公开(公告)日：2003-05-15
申请号：PCT/SE2002/002048
申请日：2002-11-08
申请人： SAHLTECH I GÖTEBORG AB , ISAKSSON, Olle , ISGAARD, Jörgen , JOHANNSSON, Gudmundur
发明人： ISAKSSON, Olle , ISGAARD, Jörgen , JOHANNSSON, Gudmundur
IPC分类号： A61K38/27
CPC分类号： A61K38/27 , A61K2300/00
摘要： The use of at least one first substance related to the growth hormone (GH) axis, and of at least one second substance, wherein said second substance upon administration to a patient leads to increased beta adrenergic receptor blockade, for the production of a pharmaceutical composition for the treatment of congestive heart failure (CHF) is disclosed. The use of said at least one first or second substance, respectively, for the production of a pharmaceutical composition for the treatment of congestive heart failure (CHF), intended for administration in combination with a pharmaceutical composition comprising said at least one second or first substance, respectively, is also disclosed. Also a method for treatment of congestive heart failure (CHF), wherein a pharmaceutically active amount of said at least one first substance is administered to a patient in combination with the administration to a patient of a pharmaceutically active amount of said at least one second substance is disclosed.
摘要翻译：使用与生长激素（GH）轴相关的至少一种第一物质和至少一种第二物质，其中所述第二物质在给予患者时导致增加的β-肾上腺素能受体阻断用于制备药物组合物用于治疗充血性心力衰竭（CHF）。分别使用所述至少一种第一或第二物质来生产用于治疗充血性心力衰竭（CHF）的药物组合物，其用于与包含所述至少一种第二或第一物质，也分别公开。还有一种治疗充血性心力衰竭（CHF）的方法，其中将药物活性量的所述至少一种第一物质与药物活性量的所述至少一种第二物质一起施用给患者被披露。

9. 发明申请

WO2010115615A1 IMPROVED GLUCOCORTICOID THERAPY 审中-公开
标题翻译：改善GLUCOCORTICOID治疗
公开(公告)号：WO2010115615A1
公开(公告)日：2010-10-14
申请号：PCT/EP2010/002178
申请日：2010-04-07
申请人： DUOCORT PHARMA AB , LENNERNÄS, Hans , JOHNSSON, Jörgen , HEDNER, Thomas , JOHANNSSON, Gudmundur , SKRTIC, Stanko
发明人： LENNERNÄS, Hans , JOHNSSON, Jörgen , HEDNER, Thomas , JOHANNSSON, Gudmundur , SKRTIC, Stanko
IPC分类号： A61K31/573 , A61P5/44
CPC分类号： A61K31/573 , A61K9/28 , A61K47/38
摘要： The present invention relates to improved glucocorticoid therapy and to treatment or prevention of a number of disorders that are due to a diminished or disrupted endogenous glucocorticoid secretory pattern. The invention is based on the findings that producing a specific serum Cortisol time profile that mimics the circadian rhythm of Cortisol of a healthy subject in a subject suffering from a diminished or disrupted glucocorticoid secretory pattern gives benefits with respect to reduction of side-effects.
摘要翻译：本发明涉及改善的糖皮质激素治疗以及治疗或预防由于内源性糖皮质激素分泌模式减少或破坏引起的许多病症。本发明基于以下发现：产生特异性血清皮质醇时间曲线，其模拟在患有糖皮质激素分泌模式减少或破坏的受试者中健康受试者的皮质醇的昼夜节律，从而有助于减少副作用。

10. 发明申请

WO2005102287A2 Pharmaceutical compositions for acute glucocorticoid therapy 审中-公开
标题翻译：急性糖皮质激素治疗药物组合物
公开(公告)号：WO2005102287A2
公开(公告)日：2005-11-03
申请号：PCT/EP2005/004399
申请日：2005-04-21
申请人： DUOCORT AB , SKRTIC, Stanko , JOHNSSON, Jörgen , LENNERNÄS, Hans , HEDNER, Thomas , JOHANNSSON, Gudmundur
发明人： SKRTIC, Stanko , JOHNSSON, Jörgen , LENNERNÄS, Hans , HEDNER, Thomas , JOHANNSSON, Gudmundur
IPC分类号： A61K9/20
CPC分类号： A61K9/0095 , A61K9/006 , A61K9/2018 , A61K9/5078 , A61K9/7007 , A61K31/00 , A61K31/573
摘要： The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid
摘要翻译：本发明涉及用于需要急性糖皮质激素治疗的急性紧急情况下的含糖皮质激素的药物组合物或试剂盒。值得注意的是，本发明涉及被设计为由医院外的非医学训练者或其他医学或临床环境施用的药物组合物和试剂盒。本发明还涉及通过提供糖皮质激素的快速起效来治疗需要急性糖皮质激素治疗的疾病的方法

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式